Acer Therapeutics Inc (NASDAQ:ACER) was up 7.2% on Friday . The company traded as high as $2.19 and last traded at $2.09, approximately 481,800 shares changed hands during trading. An increase of 206% from the average daily volume of 157,661 shares. The stock had previously closed at $1.95.
A number of equities analysts have recently weighed in on ACER shares. Roth Capital lowered their target price on Acer Therapeutics from $66.00 to $9.00 in a research note on Tuesday, June 25th. Raymond James downgraded Acer Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 25th. ValuEngine raised Acer Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research raised Acer Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Finally, Needham & Company LLC downgraded Acer Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Acer Therapeutics presently has an average rating of “Hold” and an average target price of $30.33.
The stock has a 50-day moving average of $3.01 and a 200-day moving average of $16.51.
A number of large investors have recently modified their holdings of ACER. Northern Trust Corp increased its holdings in Acer Therapeutics by 5.7% in the fourth quarter. Northern Trust Corp now owns 33,572 shares of the biopharmaceutical company’s stock valued at $676,000 after purchasing an additional 1,797 shares during the last quarter. Geode Capital Management LLC grew its stake in Acer Therapeutics by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 35,736 shares of the biopharmaceutical company’s stock valued at $719,000 after acquiring an additional 4,297 shares during the period. SG Americas Securities LLC acquired a new position in Acer Therapeutics in the first quarter valued at about $101,000. Laurion Capital Management LP acquired a new position in Acer Therapeutics in the first quarter valued at about $253,000. Finally, Sphera Funds Management LTD. acquired a new position in Acer Therapeutics in the first quarter valued at about $1,215,000. 31.05% of the stock is currently owned by institutional investors and hedge funds.
Acer Therapeutics Company Profile (NASDAQ:ACER)
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Read More: Stochastic Momentum Index (SMI)
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.